29.1 Identify the etiology, pathophysiology, and clinical ...

NCSI is an independent, physician-led collaboration to improve outcomes in cardiogenic shock. The Company announces the STEMI DTU FDA safety and feasibility study will be presented in the Late-Breaking Clinical Trials at 10:00 a.m. CST on November 11th at the American Heart Association (AHA) Scientific Sessions in Chicago. ................
................